Gate Bioscience

Gate Bioscience

生物技术研究

Brisbane, CA,California 1,927 位关注者

A new frontier of protein elimination

关于我们

Gate Bioscience is a preclinical biotechnology company creating a new class of medicines called Molecular Gates. Molecular Gates are small molecule drugs that selectively eliminate harmful extracellular proteins at their origin: inside the cell. Humans produce over 4,000 distinct extracellular proteins, more than 1,000 of which can drive disease when they act improperly, misfold, or are made at the wrong time, in the wrong place, or at incorrect levels. By eliminating these disease-causing proteins, we aim to eliminate diseases for patients. Molecular Gates act by a completely new therapeutic mechanism. All extracellular proteins pass through single channel in the cell as they are secreted into the body. Molecular Gates bind to this channel, setting up a “gate” that recognizes and blocks a specific, disease-causing protein from exiting. With nowhere to go, the harmful protein is degraded by the cell instead of being secreted. Our mission to create Molecular Gate medicines is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at www.gatebio.com.

网站
https://www.gatebio.com
所属行业
生物技术研究
规模
11-50 人
总部
Brisbane, CA,California
类型
私人持股
创立
2021

地点

Gate Bioscience员工

动态

相似主页

查看职位

融资